About NewAmsterdam Pharma
NewAmsterdam Pharma is a company based in Naarden (Netherlands) founded in 2019 by John Kastelein. NewAmsterdam Pharma has raised $196 million across 1 funding round from investors including Kaiser Permanente, Janus Henderson Investors and Life Sciences Partners. The company has 68 employees as of December 31, 2024. NewAmsterdam Pharma offers products and services including Obicetrapib. NewAmsterdam Pharma operates in a competitive market with competitors including Tenaya Therapeutics, Cellino, Enliven Therapeutics, Nuvalent and Arrakis Therapeutics, among others.
- Headquarter Naarden, Netherlands
- Employees 68 as on 31 Dec, 2024
- Founders John Kastelein
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Newamsterdam Pharma Company N.V.
-
Annual Revenue
$45.56 M (USD)223.37as on Dec 31, 2024
-
Net Profit
-$241.6 M (USD)-36.54as on Dec 31, 2024
-
EBITDA
-$176.18 M (USD)2.53as on Dec 31, 2024
-
Total Equity Funding
$196 M (USD)
in 1 rounds
-
Latest Funding Round
$196 M (USD), Series A
Jan 14, 2021
-
Investors
Kaiser Permanente
& 8 more
-
Employee Count
68
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of NewAmsterdam Pharma
NewAmsterdam Pharma is a publicly listed company on the NASDAQ with ticker symbol NAMS in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of NewAmsterdam Pharma
NewAmsterdam Pharma offers a comprehensive portfolio of products and services, including Obicetrapib.
Investigational CETP inhibitor to lower LDL-C and reduce cardiovascular risk.
People of NewAmsterdam Pharma
Unlock access to complete
Unlock access to complete
Funding Insights of NewAmsterdam Pharma
NewAmsterdam Pharma has successfully raised a total of $196M through 1 strategic funding round. The most recent funding activity was a Series A round of $196 million completed in January 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in NewAmsterdam Pharma
NewAmsterdam Pharma has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include Kaiser Permanente, Janus Henderson Investors and Life Sciences Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Multiple sectors are invested in by Morningside, a VC fund.
|
Locked | Locked | Locked | |
|
Venture capital firm focused on lifescience and healthcare sectors
|
Locked | Locked | Locked | |
|
US private equity investments are managed by BVF Partners.
|
Locked | Locked | Locked |
Investor details for NewAmsterdam Pharma
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by NewAmsterdam Pharma
Investment portfolio details for NewAmsterdam Pharma
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - NewAmsterdam Pharma
Detailed financials for NewAmsterdam Pharma
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Newamsterdam Pharma Comparisons
Peer comparison for NewAmsterdam Pharma
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of NewAmsterdam Pharma
NewAmsterdam Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Tenaya Therapeutics, Cellino, Enliven Therapeutics, Nuvalent and Arrakis Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Regenerative and gene therapeutics for heart failure are developed.
|
|
| Locked | Locked | Locked |
Developer of autologous cell therapies
|
|
| Locked | Locked | Locked |
Developer of drugs for solid tumours and blood cancers
|
|
| Locked | Locked | Locked |
Therapeutic solutions for cancer, including NSCLC inhibitors, are developed.
|
|
| Locked | Locked | Locked |
Provider of tools for the analysis of RNA structures
|
|
| Locked | Locked | Locked |
Specialized drugs are developed for genetic heart diseases.
|
Detailed competitors of NewAmsterdam Pharma
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Newamsterdam Pharma
Complete news archive for NewAmsterdam Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about NewAmsterdam Pharma
NewAmsterdam Pharma was founded in 2019 and raised its 1st funding round 2 years after it was founded.
NewAmsterdam Pharma is headquartered in Naarden, Netherlands. It is registered at Naarden, North Holland, Netherlands.
Michael Davidson is the current CEO of NewAmsterdam Pharma.
NewAmsterdam Pharma is a funded company, having raised a total of $196M across 1 funding round to date.
As of Dec 31, 2024, the latest employee count at NewAmsterdam Pharma is 68.
Annual revenue of NewAmsterdam Pharma is $45.56M as on Dec 31, 2024.
NewAmsterdam Pharma was founded in 2019 and is based in Naarden, Netherlands. Focus is placed on the pharmaceutical sector, where small molecule therapies for cardio-metabolic and cardio-renal diseases are developed. Obicetrapib, an oral cholesterol ester transfer protein inhibitor, is advanced to target Apolipoprotein B and low-density lipoprotein cholesterol levels. Operations involve clinical development of these treatments for related metabolic conditions.
NewAmsterdam Pharma's top competitors include Esperion Therapeutics, Tenaya Therapeutics and Nuvalent.
NewAmsterdam Pharma offers Obicetrapib.
Yes, NewAmsterdam Pharma is publicly traded on NASDAQ under the ticker symbol NAMS.
NewAmsterdam Pharma has 9 investors. Key investors include Kaiser Permanente, Janus Henderson Investors, Life Sciences Partners, Medpace, and Morningside.
The ticker symbol of NewAmsterdam Pharma is NAMS on NASDAQ.